Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjusted-dose DOX in Advanced Gastric Adenocarcinoma
NCT00733616Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Nov 2008
- Primary completion
- May 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin and capecitabine in gastric adenocarcinoma, sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Objective Response Rate. Started Nov 2008; status: completed.
02
Drugs
docetaxeloxaliplatincapecitabine
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT00733616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00733616.